vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Down 34.3% in March

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 16,100 shares, a decline of 34.3% from the March 15th total of 24,500 shares. Based on an average trading volume of 22,400 shares, the days-to-cover ratio is presently 0.7 days. Approximately 1.1% of the shares of the stock are short sold.

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. JPMorgan Chase & Co. bought a new position in vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 1,803 shares of the biotechnology company's stock, valued at approximately $25,000. JPMorgan Chase & Co. owned 0.06% of vTv Therapeutics as of its most recent filing with the Securities & Exchange Commission. 17.51% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on VTVT shares. StockNews.com started coverage on vTv Therapeutics in a report on Wednesday, April 16th. They set a "sell" rating for the company. HC Wainwright started coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They issued a "buy" rating and a $36.00 target price for the company.

vTv Therapeutics Trading Down 2.2 %

Shares of VTVT traded down $0.44 on Tuesday, reaching $19.23. 1,589 shares of the company's stock were exchanged, compared to its average volume of 23,022. The business has a 50 day moving average price of $18.08 and a two-hundred day moving average price of $16.00. vTv Therapeutics has a 12 month low of $12.12 and a 12 month high of $29.19. The stock has a market capitalization of $61.34 million, a P/E ratio of -4.29 and a beta of 0.81.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The company had revenue of $0.02 million during the quarter.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.